Krilogy Financial
ONCE

Krilogy Financial’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Krilogy Financial’s Portfolio ONCE Stock Details ONCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-100
Closed -$5K – 795
2018
Q3 		$5K Buy
+100
New +$6.84K ﹤0.01% 633
2018
Q2 		– Sell
-100
Closed -$7K – 715
2018
Q1 		$7K Buy
+100
New +$5.78K ﹤0.01% 574

Other funds holding ONCE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Krilogy Financial's ONCE Position: Q4 2018 in Review

Krilogy Financial sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2018, closing a stake of 100 shares — an estimated $5K sold.

Krilogy Financial first reported a position in ONCE in Q1 2018 and held it in 2 quarters. The position peaked at $7K in Q1 2018. 157 funds tracked by Wall St. Rank hold ONCE as of Q4 2018.

  • Krilogy Financial reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Krilogy Financial sold 100 Spark Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $5K.
  • Krilogy Financial first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2018 and held it in 2 quarters.
  • Krilogy Financial's Spark Therapeutics, Inc. Common Stock position peaked at $7K in Q1 2018.
  • 157 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.